1246532-96-6

Basic information

• Product Name: Tert-butyl 4-(4-aMino-3-Methoxyphenyl)piperazine-1-carboxylate
• Synonyms: Tert-butyl 4-(4-aMino-3-Methoxyphenyl)piperazine-1-carboxylate
• CAS NO: 1246532-96-6
• Molecular Weight: 307.393
• Mol File: 1246532-96-6.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: Tert-butyl 4-(4-aMino-3-Methoxyphenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-butyl 4-(4-aMino-3-Methoxyphenyl)piperazine-1-carboxylate(1246532-96-6)
• EPA Substance Registry System: Tert-butyl 4-(4-aMino-3-Methoxyphenyl)piperazine-1-carboxylate(1246532-96-6)

Safety Data

• Hazardous Substances Data: 1246532-96-6(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate is a chemical compound with a molecular structure consisting of a piperazine ring with a tert-butyl and a carboxylate group attached to the nitrogen and carbon atoms, respectively. It also contains a 4-amino-3-methoxyphenyl moiety attached to the piperazine ring. Tert-butyl 4-(4-aMino-3-Methoxyphenyl)piperazine-1-carboxylate is commonly used in pharmaceutical research and development as a potential therapeutic agent due to its ability to modulate specific biological targets in the body. It may have potential applications in the treatment of various diseases and disorders, including neurological and psychiatric conditions. Additionally, its unique structure and properties make it a valuable tool for studying the mechanisms of action of certain drugs and their interactions with target proteins in the body.

Upstream product

• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1017782-79-4 tert-butyl 4-(3-methoxy-4-nitrophenyl)piperazine-1-carboxylate 

Downstream Products

• 1254783-97-5 tert-butyl 4-(4-(5-chloro-4-(3-nitrophenoxy)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 

Relevant articles and documents

Discovery and structure ? activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Internal tandem duplications of FLT3 (FLT3-ITD) occur in approximately 25% of all acute myeloid leukemia (AML) cases and confer a poor prognosis. Optimization of the screening hit 1 from our in-house compound library led to the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives as potent and selective FLT3-ITD inhibitors. Compounds 17 and 19 displayed potent FLT3-ITD activities both with IC50 values of 0.4 nM and excellent antiproliferative activities against AML cell lines. Especially, compounds 17 and 19 inhibited the quizartinib resistance- conferring mutations, FLT3D835Y, both with IC50 values of 0.3 nM. Moreover, western blot analysis indicated that compounds 17 and 19 potently inhibited the phosphorylation of FLT3 and attenuated downstream signaling in AML cells. These results indicated that pyrazolo[1,5-a]pyrimidine derivatives could be promising FLT3-ITD inhibitors for the treatment AML.

PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE

The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.

Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders

The first examples of threonine tyrosine kinase (TTK) PROTACs were designed and synthesized. Two of the most potent molecules, 8e and 8j, demonstrated strong TTK degradation in COLO-205 human colorectal cancer cells with DC50 values of 1.7 and 3.1 nM, respectively. Proteasome-mediated degradation by the compounds could last for approximately 8 h after washout. The degraders 8e and 8j demonstrated improved antiproliferative activities comparing with the structurally similar inhibitor counterparts 8q and 8r. Degraders 8e and 8j also demonstrated reasonable PK profiles and exhibited potent target degradation and in vivo anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells upon i.p. administration.